Mometasone Furoate
drugOn this page
Also known as AsmanexAsmanex hfaAsmanex twisthalerEloconLAS-41002LAS41002Lyr-210LYR210Mometasone furoate anhydrousMometasone furoate component of duleraMometasone furoate component of ryaltrisMometasone furoate hydrateMometasone furoate monohydrateMonovoNasonexNasonex 24hr allergyNSC-746171NSC-760077SCH 32088
Summary
Mometasone Furoate (CHEMBL1161) is an approved small-molecule anti-inflammatory drug (ATC D07AC13); indicated across 26 conditions including allergic rhinitis and obstructive lung disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: D07AC13 (+3 more)
- Indications: 26 conditions
- Clinical trials: 87
- Chemistry: 521.4 Da · C27H30Cl2O6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1161 |
| Name | Mometasone Furoate |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 441336 |
| ChEBI | CHEBI:47564 |
| ATC | D07AC13, D07XC03, R01AD09, R03BA07 |
| Molecular formula | C27H30Cl2O6 |
| Molecular weight | 521.4 |
| InChIKey | WOFMFGQZHJDGCX-ZULDAHANSA-N |
SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)OC(=O)C5=CC=CO5)C)O)Cl)C
IUPAC name: [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
Pharmacological roles (ChEBI): anti-inflammatory drug, anti-allergic agent.
Also known as: Asmanex, Asmanex hfa, Asmanex twisthaler, Elocon, LAS-41002, LAS41002, Lyr-210, LYR-210, LYR210, Mometasone furoate, Mometasone furoate anhydrous, Mometasone furoate component of dulera
Patent coverage: 6,585 distinct patent families (25,884 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Solute carrier organic anion transporter family member 1B1, Solute carrier organic anion transporter family member 1B3, Androgen receptor, Beta-lactamase, Glucocorticoid receptor, Progesterone receptor, Prostaglandin G/H synthase 1, Adenosine receptor A3, Bile salt export pump.
Bioactivity
ChEMBL activities: 13 potent at pChembl ≥ 5 of 14 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| PGR | 10.1 | Kd | 0.08 | nM | CHEMBL_ACT_693700 |
| NR3C1 | 9.3 | AC50 | 0.5 | nM | CHEMBL_ACT_25176338 |
| NR3C1 | 9.15 | Ki | 0.7 | nM | CHEMBL_ACT_18916453 |
| NR3C1 | 8.55 | AC50 | 2.8 | nM | CHEMBL_ACT_25116244 |
| PGR | 8.52 | AC50 | 3 | nM | CHEMBL_ACT_25204804 |
| AR | 7.47 | AC50 | 33.7 | nM | CHEMBL_ACT_25203871 |
| SLCO1B3 | 6.06 | Ki | 870 | nM | CHEMBL_ACT_13798710 |
| SLCO1B3 | 5.94 | IC50 | 1148 | nM | CHEMBL_ACT_13798644 |
| SLCO1B1 | 5.79 | Ki | 1620 | nM | CHEMBL_ACT_13800709 |
| ADORA3 | 5.78 | AC50 | 1644 | nM | CHEMBL_ACT_25199126 |
| ABCB11 | 5.62 | AC50 | 2400 | nM | CHEMBL_ACT_25127227 |
| SLCO1B1 | 5.53 | IC50 | 2951 | nM | CHEMBL_ACT_13800643 |
| P00811 | 5 | Potency | 10000 | nM | CHEMBL_ACT_4679809 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
26 indications (8 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| allergic rhinitis | 4 | MONDO:0011786 | EFO:0005854 |
| obstructive lung disease | 4 | MONDO:0002267 | HP:0006536 |
| seasonal allergic rhinitis | 4 | MONDO:0005324 | EFO:0003956 |
| nasal cavity polyp | 4 | MONDO:0006314 | EFO:1000391 |
| skin disorder | 4 | MONDO:0005093 | EFO:0000701 |
| asthma | 4 | MONDO:0004979 | MONDO:0004979 |
| chronic obstructive pulmonary disease | 3 | MONDO:0005002 | EFO:0000341 |
| obstructive sleep apnea syndrome | 3 | MONDO:0007147 | EFO:0003918 |
| sinusitis | 3 | MONDO:0005961 | EFO:0007486 |
| perennial allergic rhinitis | 3 | MONDO:0024332 | EFO:1001417 |
| breast neoplasm | 3 | MONDO:0021100 | MONDO:0007254 |
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
| atopic eczema | 2 | MONDO:0004980 | EFO:0000274 |
| psoriasis | 2 | MONDO:0005083 | EFO:0000676 |
| eosinophilic esophagitis | 2 | MONDO:0005361 | EFO:0004232 |
| bullous pemphigoid | 2 | MONDO:0019082 | EFO:0007187 |
| sickle cell disease | 2 | MONDO:0011382 | MONDO:0011382 |
| radiodermatitis | 2 | MONDO:0043771 | MONDO:0043771 |
| allergic disease | 1 | MONDO:0005271 | MONDO:0005271 |
| spinal cord injury | 1 | MONDO:0043797 | MONDO:0043797 |
| otitis media with effusion | 0 | MONDO:0005892 | EFO:0007415 |
| alopecia areata | 0 | MONDO:0005340 | EFO:0004192 |
4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 87.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 34 |
| PHASE2 | 21 |
| PHASE4 | 18 |
| PHASE1 | 7 |
| Not specified | 6 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06399783 | PHASE4 | NOT_YET_RECRUITING | Topical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata |
| NCT00236106 | PHASE4 | COMPLETED | Short Term Growth in Children With Atopic Dermatitis |
| NCT00442351 | PHASE4 | TERMINATED | Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED) |
| NCT00687531 | PHASE4 | TERMINATED | Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate in Asthmatic Patients (Study P04879)(TERMINATED) |
| NCT00711165 | PHASE4 | COMPLETED | Mometasone and Markers of Airway Inflammation |
| NCT00834119 | PHASE4 | COMPLETED | Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Oral Antihistamine (Study P03270) |
| NCT00835094 | PHASE4 | COMPLETED | A Randomized Trial Assessing Once Daily Administration of Mometasone Furoate DPI in Asthmatics (Study P02177) |
| NCT01118312 | PHASE4 | COMPLETED | Study of Asthma and Nasal Steroids |
| NCT01333410 | PHASE4 | UNKNOWN | Comparison of Efficacy and Safety of 0.1% Tacrolimus and 0.1% Mometasone Furoate for Adult Vitiligo |
| NCT01471340 | PHASE4 | COMPLETED | A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241) |
| NCT01616160 | PHASE4 | TERMINATED | An Open-label Study to Identify Molecular Markers of Steroid Resistance |
| NCT01635088 | PHASE4 | COMPLETED | Onset and Duration of Mometasone by Oscillometry and Spirometry |
| NCT01861145 | PHASE4 | WITHDRAWN | Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea |
| NCT02559440 | PHASE4 | COMPLETED | Mometasone Furoate and Oxymetazoline in the Treatment of Adenoid Hypertrophy |
| NCT04271007 | PHASE4 | COMPLETED | Comparative Study:Topison (Mometasone Furoate) Versus Two Others Mometasone Furoates |
| NCT04898764 | PHASE4 | COMPLETED | Research on Underlying Causes of Long-term Use of Nasal Decongestants and the Structured Withdrawal of the Decongestant |
| NCT05382494 | PHASE4 | COMPLETED | Intranasal Steroid as Medical Therapy For Sleep-Disordered Breathing in Children |
| NCT05578482 | PHASE4 | UNKNOWN | Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis |
| NCT07311759 | PHASE3 | ACTIVE_NOT_RECRUITING | Safety and Efficacy of Intralesional 0.5% Triamcinolone Acetonide in 0.2% Fluconazole Solution vs 0.1% Topical Mometasone Furoate With 2% Miconazole Nitrate Cream in the Treatment of Chronic Paronychia: An Intraindividual Randomized Controlled Trial. |
| NCT00224523 | PHASE3 | COMPLETED | Long Term Safety Of GW685698X Via Nasal Biopsy |
| NCT00381485 | PHASE3 | COMPLETED | Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED) |
| NCT00383240 | PHASE3 | COMPLETED | Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED) |
| NCT00383435 | PHASE3 | COMPLETED | Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED) |
| NCT00383552 | PHASE3 | COMPLETED | Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED) |
| NCT00383721 | PHASE3 | COMPLETED | Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED) |
| NCT00424008 | PHASE3 | COMPLETED | Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1) |
| NCT00438659 | PHASE3 | COMPLETED | Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ |
| NCT00453063 | PHASE3 | COMPLETED | Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED) |
| NCT00550550 | PHASE3 | COMPLETED | Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) |
| NCT00720382 | PHASE3 | COMPLETED | A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis |
| NCT00732368 | PHASE3 | COMPLETED | A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis (Study P04459) |
| NCT00779740 | PHASE3 | COMPLETED | Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study P04419) |
| NCT00975741 | PHASE3 | COMPLETED | Efficacy and Safety of Two Dry Power Inhalers (DPIs) Used for the Application of Mometasone in the Treatment of Asthma |
| NCT01038427 | PHASE3 | COMPLETED | A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis |
| NCT01135134 | PHASE3 | COMPLETED | Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332) |
| NCT01165424 | PHASE3 | COMPLETED | A Study of Long-term Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06333AM1) |
| NCT01372865 | PHASE3 | COMPLETED | A Clinical Trial About Treatment of Mild to Moderate Persistent Alergic Rhinnitis With Test or Reference Mometasone (PUMA) |
| NCT01470053 | PHASE3 | COMPLETED | Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis |
| NCT01566149 | PHASE3 | COMPLETED | Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212) |
| NCT01673659 | PHASE3 | COMPLETED | A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).